SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

59.85 0.5

Buy Sell

Overview

Share price change

24h

Current

Min

59.25

Max

Key metrics
By Trading Economics
Income	-33M 9.5M
Sales	-66M 152M
P/E Sector Avg	24.576 49.701
EPS	0.185
Profit margin	6.216
Employees	1,950
EBITDA	-45M 18M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+26.46% upside

Dividends
By Dow Jones
Next Earnings	23 lip 2026

Market Stats
By TradingEconomics
Market Cap	-1.1B 3B
Previous open	59.35
Previous close	59.85

News Sentiment

By Acuity

50%

159 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

51.1 / N/A Support & Resistance

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 maj 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 maj 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 maj 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 maj 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 maj 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 maj 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 maj 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 maj 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 maj 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 maj 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 maj 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 maj 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 maj 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 maj 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 maj 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 maj 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 maj 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 maj 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

26.46% upside

12 Months Forecast

Average 73.6 EUR 26.46%

High 83 EUR

Low 64.2 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

159 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.